HBM bids for rival Swiss life science VC

HBM BioVentures is poised to acquire fellow Swiss life science investor International BM Biomedicine, following the recommendation of its CHF80m offer by the target company’s directors.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this